Unsplash+Most inflammatory arthritis patients on MoonLake Immunotherapeutics’ sonelokimab met the response criteria, furthering the Swiss biotech’s attempt to challenge UCB for a blockbuster market.
ADVERTISEMENT
Most inflammatory arthritis patients on MoonLake Immunotherapeutics’ sonelokimab met the response criteria, furthering the Swiss biotech’s attempt to challenge UCB for a blockbuster market.